PGDx CancerSELECT 125 Test
Dec 21, 2016
Personal Genome Diagnostics has launched the CancerSELECT 125 test for pan-cancer tumor profiling. The test identifies clinically actionable and functionally important sequence mutations, and structural alterations across multiple cancer types using the company's proprietary technologies and bioinformatics. The test also reports microsatellite instability status to assess potential response to checkpoint inhibitor therapies. Additionally, it includes matched sequencing of normal patient tissue to accurately filter out germline variants.